Rentschler Biopharma Expands Services in Japan & South Korea

Rentschler Biopharma SE, a global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is expanding its services in Japan and South Korea.

With their well-established and growing biopharma industries, Japan and South Korea are key markets for biopharmaceutical development. Rentschler Biopharma has been active in the region for many years, serving a wide range of clients, with support from its established regional partner, Summit Pharmaceuticals International (SPI).

“We at Rentschler Biopharma are deeply grateful for the trust placed in us by our client partners in Japan and South Korea, and we look forward to deepening these relationships as well as building new strategic partnerships through continued collaboration,” commented Benedikt von Braunmühl, CEO at Rentschler Biopharma.

To tailor its process development and manufacturing services to Japanese clients, Rentschler Biopharma is collaborating closely with SPI as its established partner, ensuring that clients benefit from seamless communication, localized regulatory insights, and culturally attuned project management.